Essa Pharma Stock Analysis
EPIX Stock | USD 5.97 0.78 11.56% |
ESSA Pharma is undervalued with Real Value of 9.25 and Target Price of 19.4. The main objective of ESSA Pharma stock analysis is to determine its intrinsic value, which is an estimate of what ESSA Pharma is worth, separate from its market price. There are two main types of ESSA Pharma's stock analysis: fundamental analysis and technical analysis.
The ESSA Pharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. ESSA Pharma is usually not traded on Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day. ESSA Stock trading window is adjusted to America/New York timezone.
ESSA |
ESSA Stock Analysis Notes
About 79.0% of the company shares are held by institutions such as insurance companies. The book value of ESSA Pharma was currently reported as 3.01. The company recorded a loss per share of 0.62. ESSA Pharma last dividend was issued on the 25th of April 2018. The entity had 1:20 split on the 25th of April 2018. ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada. Essa Pharma is traded on NASDAQ Exchange in the United States. To learn more about ESSA Pharma call David MD at 778 331 0962 or check out https://www.essapharma.com.ESSA Pharma Investment Alerts
ESSA Pharma generated a negative expected return over the last 90 days | |
ESSA Pharma has high historical volatility and very poor performance | |
Net Loss for the year was (26.58 M) with profit before overhead, payroll, taxes, and interest of 0. | |
ESSA Pharma currently holds about 174.6 M in cash with (19.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96. | |
ESSA Pharma has a very weak financial position based on the latest SEC disclosures | |
Over 79.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from finance.yahoo.com: ESSA Pharma to Present at the Jefferies Global Healthcare Conference |
ESSA Pharma Upcoming and Recent Events
Earnings reports are used by ESSA Pharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ESSA Pharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
6th of February 2024 Upcoming Quarterly Report | View | |
14th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
10th of December 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
30th of September 2023 Last Financial Announcement | View |
ESSA Largest EPS Surprises
Earnings surprises can significantly impact ESSA Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2023-08-08 | 2023-06-30 | -0.19 | -0.17 | 0.02 | 10 | ||
2016-02-12 | 2015-12-31 | -0.17 | -0.19 | -0.02 | 11 | ||
2024-02-13 | 2023-12-31 | -0.17 | -0.14 | 0.03 | 17 |
ESSA Pharma Environmental, Social, and Governance (ESG) Scores
ESSA Pharma's ESG score is a quantitative measure that evaluates ESSA Pharma's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of ESSA Pharma's operations that may have significant financial implications and affect ESSA Pharma's stock price as well as guide investors towards more socially responsible investments.
ESSA Stock Institutional Investors
Shares | Parkman Healthcare Partners Llc | 2024-03-31 | 251.7 K | Cibc World Markets Inc. | 2024-03-31 | 80.9 K | D. E. Shaw & Co Lp | 2024-03-31 | 65.1 K | Bnp Paribas Arbitrage, Sa | 2023-12-31 | 57.5 K | American Century Companies Inc | 2024-03-31 | 46.2 K | Royal Bank Of Canada | 2024-03-31 | 30.8 K | Geode Capital Management, Llc | 2024-03-31 | 26.9 K | Renaissance Technologies Corp | 2023-12-31 | 24.2 K | Privium Fund Management (uk) Ltd | 2023-12-31 | 20 K | Bvf Inc | 2024-03-31 | 8.7 M | Bellevue Group Ag | 2024-03-31 | 7.9 M |
ESSA Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 300 M.ESSA Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.16) | (0.17) | |
Return On Capital Employed | (0.16) | (0.17) | |
Return On Assets | (0.16) | (0.17) | |
Return On Equity | (0.21) | (0.20) |
Management Efficiency
ESSA Pharma has return on total asset (ROA) of (0.144) % which means that it has lost $0.144 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1914) %, meaning that it created substantial loss on money invested by shareholders. ESSA Pharma's management efficiency ratios could be used to measure how well ESSA Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.17 in 2024. Return On Capital Employed is likely to drop to -0.17 in 2024. At this time, ESSA Pharma's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 201.8 M in 2024, whereas Other Current Assets are likely to drop slightly above 639.6 K in 2024.Last Reported | Projected for Next Year | ||
Book Value Per Share | 2.97 | 2.20 | |
Net Current Asset Value | 3.6 M | 3.2 M | |
Tangible Asset Value | 3.7 M | 3.3 M | |
Tangible Book Value Per Share | 2.97 | 2.10 | |
Enterprise Value Over EBITDA | (3.49) | (3.66) | |
Price Book Value Ratio | 0.84 | 0.88 | |
Enterprise Value Multiple | (3.49) | (3.66) | |
Price Fair Value | 0.84 | 0.88 | |
Enterprise Value | 92.4 M | 97 M |
The analysis of ESSA Pharma's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze ESSA Pharma's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of ESSA Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 1.759 |
Technical Drivers
As of the 3rd of June, ESSA Pharma shows the Mean Deviation of 2.64, market risk adjusted performance of (5.95), and Standard Deviation of 3.59. ESSA Pharma technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to collect and analyze data for thirteen technical drivers for ESSA Pharma, which can be compared to its peers. Please confirm ESSA Pharma market risk adjusted performance and treynor ratio to decide if ESSA Pharma is priced fairly, providing market reflects its regular price of 5.97 per share. Given that ESSA Pharma has information ratio of (0.19), we urge you to verify ESSA Pharma's prevailing market performance to make sure the company can sustain itself at some point in the future.ESSA Pharma Price Movement Analysis
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. ESSA Pharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for ESSA Pharma. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
ESSA Pharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ESSA Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on ESSA Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ESSA Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ESSA Pharma Predictive Daily Indicators
ESSA Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ESSA Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
ESSA Pharma Corporate Filings
10Q | 14th of May 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F4 | 6th of May 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 25th of April 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
5th of April 2024 Other Reports | ViewVerify | |
F4 | 28th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 7th of March 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 5th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of February 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
ESSA Pharma Forecast Models
ESSA Pharma's time-series forecasting models are one of many ESSA Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ESSA Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About ESSA Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how ESSA Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling ESSA shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as ESSA Pharma. By using and applying ESSA Stock analysis, traders can create a robust methodology for identifying ESSA entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | -53.9 K | -56.6 K | |
Operating Profit Margin | -81.5 K | -85.5 K | |
Net Loss | -54.5 K | -57.2 K | |
Gross Profit Margin | 0.00 | 0.00 |
Current ESSA Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. ESSA analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. ESSA analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
19.4 | Strong Buy | 5 | Odds |
Most ESSA analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand ESSA stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of ESSA Pharma, talking to its executives and customers, or listening to ESSA conference calls.
ESSA Stock Analysis Indicators
ESSA Pharma stock analysis indicators help investors evaluate how ESSA Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading ESSA Pharma shares will generate the highest return on investment. By understating and applying ESSA Pharma stock analysis, traders can identify ESSA Pharma position entry and exit signals to maximize returns.
Begin Period Cash Flow | 57.1 M | |
Common Stock Shares Outstanding | 44.1 M | |
Total Stockholder Equity | 145.6 M | |
Tax Provision | 1600.00 | |
Property Plant And Equipment Net | 68 K | |
Cash And Short Term Investments | 148.1 M | |
Cash | 33.7 M | |
Accounts Payable | 2 M | |
Net Debt | -33.6 M | |
50 Day M A | 7.0764 | |
Total Current Liabilities | 3.5 M | |
Other Operating Expenses | 32.1 M | |
Non Current Assets Total | 325.3 K | |
Non Currrent Assets Other | 257.2 K | |
Stock Based Compensation | 5 M |
Additional Tools for ESSA Stock Analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.